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Abstract 
Background: De novo variants in the voltage‑gated calcium channel subunit α1 E gene (CACNA1E) have been 
described as causative of epileptic encephalopathy with contractures, macrocephaly and dyskinesias.
Methods: Following the observation of an index patient with developmental delay and autism spectrum disorder 
(ASD) without seizures who had a de novo deleterious CACNA1E variant, we screened GeneMatcher for other individu‑
als with CACNA1E variants and neurodevelopmental phenotypes without epilepsy. The spectrum of pathogenic CAC-
NA1E variants was compared to the mutational landscape of variants in the gnomAD control population database.
Results: We identified seven unrelated individuals with intellectual disability, developmental regression and ASD‑
like behavioral profile, and notably without epilepsy, who had de novo heterozygous putatively pathogenic variants 
in CACNA1E. Age of onset of clinical manifestation, presence or absence of regression and degree of severity were 
variable, and no clear‑cut genotype–phenotype association could be recognized. The analysis of disease‑associated 
variants and their comparison to benign variants from the control population allowed for the identification of regions 
in the CACNA1E protein that seem to be intolerant to substitutions and thus more likely to harbor pathogenic vari‑
ants. As in a few reported cases with CACNA1E variants and epilepsy, one patient showed a positive clinical behavioral 
response to topiramate, a specific calcium channel modulator.
Limitations: The significance of our study is limited by the absence of functional experiments of the effect of identi‑
fied variants, the small sample size and the lack of systematic ASD assessment in all participants. Moreover, topiramate 
was given to one patient only and for a short period of time.
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Background
Voltage-gated calcium channels (VGCCs) are pro-
teins that regulate the entry of calcium ions  (Ca2+)  in 
response to depolarization of the cellular membrane 
of excitable cells [1] and represent principal gateways 
for  Ca2+ in nerve and both skeletal and cardiac muscle 
cells [2]. VGCCs are constituted by 5 different subunits, 
α1, α2, β, δ, γ, which together form the high-voltage-
activated  Ca2+ channels [3]. The α1 subunit is the main 
subunit indispensable for the functioning of the chan-
nel. It is composed of four homologous domains (I–IV), 
each containing 6 transmembrane segments, including 
a voltage sensor segment (S4) and 2 segments forming 
a pore (S5–S6) [1]. In mammals, ten α1 subunits have 
been described, encoded by ten different genes. Each of 
these subunits has specific molecular, genetic, physio-
logic and pharmacological properties [1, 4], and patho-
genic variants in these genes have been associated with 
various human diseases and represent putative targets 
for treatment [5].
The α1E gene (CACNA1E) encodes the high-volt-
age-activated Cav2.3 type R calcium channel, which is 
expressed in various areas of the central nervous sys-
tem, including the cerebellum [1]. More specifically, it 
is involved in the initiation of the presynaptic calcium 
entry and post-synaptic transmitter release [6].
CACNA1E variants were initially associated with sei-
zures (Baker JJ 2016: http:// epost erson line. com/ acmg2 
016/ node/ 2302) and with autism spectrum disorder 
(ASD) [7]. Other studies found a possible impact of 
CACNA1E single nucleotide polymorphisms in dif-
ferent human diseases and disorders including dia-
betes [8], migraine [9] and pain regulation [10]. More 
recently, the pathogenic role of CACNA1E variants in 
human epilepsy and neurodevelopmental disorders 
(NDD) has been described. One large genomic study 
of trios presenting with NDD identified CACNA1E as a 
candidate gene for NDD with or without epilepsy [11], 
and subsequently, variants in CACNA1E have been 
found in patients with developmental and epileptic 
encephalopathy (DEE) [12]. A large multiplex gene net-
work analysis identified CACNA1E as candidate gene 
for epilepsy and autism [13]. Subsequently, a genetic 
association between calcium channels in general and 
ASD was further suggested by Liao and Li [14] and 
Graziano et al. [15].
The largest cohort of CACNA1E patients, described 
by Helbig et  al. [12], reports 30 patients, aged between 
1 and 16  years, who presented with severe to profound 
developmental delay and a combination of epilepsy, tone 
disorders and/or abnormal movements. Among these 
individuals, 88% were described as non-verbal and non-
ambulatory. Of the 30 patients, 29 patients presented 
with hypotonia, six presented with spastic quadriple-
gia, 13 with joint contractures, 14 with extrapyramidal 
signs, and 26 with epilepsy (among these, 14 had epilep-
tic spasms). Nine patients presented with developmen-
tal regression associated with the onset of epilepsy [12]. 
Interestingly, topiramate was the main anti-seizure drug 
reported to show a reduction in seizure presentation. 
Functional analysis of the Cav2.3 channel in 14 patients 
revealed a gain-of-function effect of the CACNA1E path-
ogenic variants with either a facilitated activation or an 
increased  Ca2+ current. As topiramate blocks R-type cal-
cium channels, among its different actions, the R-type 
calcium current might represent a common neuropatho-
genic mechanism involved in epilepsy and developmental 
delay [16].
We identified a de novo missense variant in CACNA1E 
in a patient with global developmental delay (GDD), 
ASD and successive developmental regressions unre-
lated to epileptic seizures. We used GeneMatcher [17] 
to seek other similar developmental patterns associated 
with CACNA1E variants, with the aim to identify possi-
ble neurodevelopmental presentations without epilepsy 
and to extend the phenotypic description of CACNA1E-
related disorders. Using large datasets of control popu-
lations, we tried to compute the mutational constraint 
within CACNA1E domains and segments to identify 
putative functionally relevant segments that are more 
likely to harbor pathogenic variants.
Method
Participants
A missense de novo variant in CACNA1E was found in 
our index patient after analysis of an extended genetic 
panel, including epilepsy and developmental delay related 
genes. His phenotype was notable for two episodes of 
Conclusions: Our results indicate that CACNA1E variants may result in neurodevelopmental disorders without epi‑
lepsy and expand the mutational and phenotypic spectrum of this gene. CACNA1E deserves to be included in gene 
panels for non‑specific developmental disorders, including ASD, and not limited to patients with seizures, to improve 
diagnostic recognition and explore the possible efficacy of topiramate.
Keywords: Autism spectrum disorder, CACNA1E, Developmental regression, Epilepsy, Exome sequencing, Global 
developmental delay, Intellectual disability, Neurodevelopmental disorders, Seizures, Topiramate
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acute regression, in the context of a pre-existing GDD 
and ASD. Notably, he never presented with any type of 
epileptic seizures, the common feature in the cohort 
described by Helbig et  al. [12]. Through GeneMatcher, 
we identified six additional patients who were carriers 
of heterozygous de novo putative deleterious variants 
in CACNA1E and presented with GDD, developmental 
regression and no epilepsy. Except for one patient aged 
2, five patients presented with behavioral disturbances 
belonging to the field of ASD, despite the lack of precise 
behavioral phenotyping required for an ASD diagnosis. 
None of these patients has been reported previously.
Sequencing and filtering of variants
Genomic DNA was extracted from whole blood from 
the patients and their parents. Exome sequencing in trios 
was done for 5/7 patients, and in the proband only for 2/7 
patients. Segregation of the CACNA1E variants was done 
by Sanger sequencing for 6/7 patients. The protocols 
and software versions used for exome capture, sequenc-
ing, next-generation sequencing (NGS) pipeline and 
analysis for each patient are available in Additional file 1: 
Table S1. All discovered variants are defined in GRCh37 
and the NM_000721.4 isoform of CACNA1E, and were 
classified following guidelines from the American Col-
lege of Medical Genetics (ACMG) [18].
Analysis of regional intolerance to missense variants 
in CACNA1E
We have downloaded the table of Missense Tolerance 
Ratio (MTR) scores for CACNA1E from MTR-Viewer 
v2 [19]. MTR is the measure of the proportion of the 
observed and expected missense variations in a gene 
given the specific protein regions, reflecting selective 
constraints of the given region. An MTR score above 1 
suggests a positive selection of the segment, MTR score 
equal to 1 indicates segments’ selective neutrality, and an 
MTR value below 1 indicates purifying selection against 
missense alterations. A false discovery rate (FDR) value 
of < 0.1 is used to determine whether MTR deviates sig-
nificantly from 1.0, to exclude false positives.
We have calculated the mean MTR score and the mean 
FDR for each CACNA1E segment, intersegment and 
interdomain regions. We computed the median, 25th 
percentile and 5th percentile MTR values (0.79, 0.60 and 
0.33, respectively). We considered regions being selected 
against missense variants if their MTR value was below 
1 with the associated FDR below 0.1, and being highly 
intolerant to missense alterations if their MTR value was 
below the 5th percentile with the respective mean FDR 
below 0.1, as previously described [20].
Results
Clinical reports
The seven patients, including the index patient and 6 
patients recruited via GeneMatcher [17], were all bearing 
hitherto undescribed de novo heterozygous variants in 
CACNA1E (see Table 1). Shared clinical features among 
these patients were GDD, marked speech and language 
delays and social behavioral deficit. Furthermore, mus-
cular hypotonia, motor stereotypies and sensory issues 
(a clinical criteria for ASD) were each reported in 5 of 
7 patients. Four patients (4/7, 57%) also presented with 
developmental regression, unrelated to any seizures or 
specific electro-encephalographic (EEG) epileptic activ-
ity. The loss of previously acquired vocabulary and of 
communicative skills seen in these patients fulfilled the 
diagnostic criteria for so-called autistic regression. One 
adult patient (Patient 4) had a history of epileptic spasms, 
successfully treated with adrenocorticotropic hormone, 
without subsequent seizures in childhood or adult-
hood. No recognizable facial phenotype was identified 
in the patients. None of the patients had epilepsy, spastic 
quadriplegia, joint contractures, extrapyramidal signs or 
macrocephaly, as described in Helbig et al. [12]. An over-
view of the major clinical features seen in our patients is 
described in Table  1, and a more complete list for each 
case is available in Additional File 1: Table S2.
The recent articles by Helbig et  al. [12] suggested the 
use of the anti-seizure drug topiramate targeting the 
Cav2.3 channel, encoded by CACNA1E, in order to man-
age the refractory epilepsy present in their patients. After 
identification of a CACNA1E variant in patient 1 in the 
current study, he received a trial of topiramate on the 
basis of a hypothesis that even despite the absence of sei-
zures, modulation of intracellular  Ca2+ influx might posi-
tively impact the behavioral phenotype. For this reason, 
we present a more detailed clinical history of this patient.
Patient 1 presented with marked developmental regres-
sion at age of 14 months with loss of first words and com-
municative gestures. Retrospectively, the development 
up to that point had been slow, particularly concerning 
speech development and communication competencies. 
Subsequently, there was slow progress in language acqui-
sition, and at age 4 years, he was diagnosed with ASD and 
GDD. At that time, the first regression episode was inter-
preted as suggestive of an autistic regression.
At age 5  years, he suddenly presented with a second 
developmental regression with motor hyperactivity, per-
vasive stereotypies (body rocking and hand stereotyp-
ies), loss of interest in play, and loss of sphincter control 
at night. Brain MRI and a metabolic assessment were 
normal. EEG showed bilateral occipital spikes, acti-
vated during sleep. He never had epileptic seizures. He 
had a severe sleep disorder. The sleep EEG monitoring 
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excluded nocturnal epileptic seizures as the cause of 
multiple awakenings. Progressive titration of topiramate 
up to 2 mg/kg/day was accompanied by improvement in 
motor hyperkinesia and social contact, and regain of noc-
turnal sphincter control. A dosage above 2.5  mg/kg/day 
was not well tolerated because of increased irritability.
Genetics findings
With exome sequencing, we identified seven novel vari-
ants in CACNA1E in seven unrelated patients. In indi-
vidual 1, a de novo missense mutation in CACNA1E, 
c.488T>C, was localized in the segment S3 of Domain I, 
leading to a p.Met163Thr change. Individual 2 carried a 
c.1499A>G de novo missense variant in the Domain II 
of CACNA1E, between segments S1 and S2, leading to 
a p.Gln500Arg change. Individuals 3 to 6 carried each a 
de novo missense variant clustering in the segment S6 
of the Domain II, c.2060C>T, c.2104G>T, c.2105C>T 
and c.2108T>G, resulting in p.Thr687Ile, p.Ala702Ser, 
p.Ala702Val and p.Val703Gly changes, respectively. Indi-
vidual 7 carried a de novo splicing variant c.3422+1G>A, 
localized at the beginning of Domain III.
These variants’ localizations on the CACNA1E struc-
ture and domains are shown in Fig.  1A, along with the 
variants described in Helbig et al. [12] and in Heyne et al. 
[11]. All residues impacted by these missense variants 
in individuals 1–6 are highly conserved and predicted 
to be deleterious by various in silico predictors (Addi-
tional file 1: Table S3). The splicing variant in individual 
7 is predicted by three splicing predictors (MaxEntS-
can, NNSPLICE, and Human Splicing Finder from Ala-
mut Visual (Interactive Biosoftware)) to disrupt exon 22 
consensus donor site. None of the seven novel variants 
reported here are present in public databases of control 
individuals (gnomAD [21], LOVD [22]).
CACNA1E is predicted to be associated mainly with 
an autosomal dominant disorder, with a high DOMINO 
score of 0.995 [23]. Bioinformatic analysis of variant types 
and distributions in gnomAD control dataset revealed a 
conspicuous absence of loss-of-function (LOF) variants 
in CACNA1E, suggesting that this gene is highly intoler-
ant to truncating mutations (gnomAD LOF metrics for 
CACNA1E: pLI = 1 and LOEUF = 0.12). CACNA1E is 
also strongly intolerant to missense variation (gnomAD 
Z score = 5.81) [21].
We used MTR region-gated analysis of missense vari-
ants [19] to infer the functional importance of the dif-
ferent segments and domains of the protein (Fig.  2). 
The significantly conserved regions (corresponding 
to MTR score below 0.33) are located in the segment 
6 of Domains I and II as well as the regions just at the 
end of Domains I and III and the intersegment S4-S5 in 
Domain I (Fig. 2). It correlates with the different clusters 
of pathogenic variants observed in the reported patients 
(Fig. 1A).
Discussion
The seven individuals (six children and one young adult) 
with heterozygous de novo pathogenic variants in CAC-
NA1E described here showed a broad phenotypic spec-
trum including intellectual disability, GDD, abnormal 
behavioral phenotypes (in three cases associated with 
clinically confirmed ASD diagnosis), hypotonia, absence 
of language or speech delay and developmental regres-
sions in infancy, but no severe neuromotor deficit or epi-
leptic seizures (except for epileptic spasms in Patient 4). 
This cohort has enabled us to broaden the genotypic and 
the phenotypic spectrum of CACNA1E-related neurode-
velopmental disorder.
The phenotype in our patients was milder than the one 
reported previously [12], which might be linked to the 
absence of refractory epilepsy. Indeed, the 30 patients 
previously reported [12] presented with a more severe 
neurodevelopmental phenotype, as the expression of a 
more severely impacted brain developmental trajectory. 
Among them, four had no epilepsy and one had no infor-
mation available for the epilepsy phenotype. The non-
epileptic patients older than 2 years (2/4, 50%) showed a 
milder phenotype than the others in the cohort, having 
single-word capacity and being ambulant. Cognitive and 
behavioral profiles reported for those patients were very 
similar to the ones seen in our cohort. However, social 
deficits were not reported in their study.
Pathogenic CACNA1E variants reported previously 
[12] and in this paper cluster mostly inside or at the end 
of segment 6 of Domains I, II and III (Fig. 1A). Based on 
the analysis of genetic intolerance, those regions are the 
most intolerant to missense variation (Fig.  2). Thus, the 
natural variant epidemiology supports the concept that 
these regions are most crucial for the normal function of 
CACNA1E [16, 24].
Based on the clinical description of the patients har-
boring the different CACNA1E variants, there seems 
to be no clear link between the localization of the vari-
ant on the protein and the clinical outcome, especially 
of refractory epilepsy or spastic quadriplegia (Fig.  1B). 
Indeed, four of the patients presented here carry mis-
sense variants impacting either the same amino acid 
(p.Ala702) or in the same clustered region of the segment 
6 in Domain II as some patients reported with severe epi-
lepsy [12]. Interestingly, among the patients without epi-
lepsy reported previously, two harbor missense variants 
also seen in patients with severe epilepsy [12]. The first 
patient is a 1-year-old girl with a p.Gly352Arg missense 
variant, a recurrent mutation seen in 8 other patients 
with a strong epilepsy phenotype, which started after 
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age 1 in 3/8 cases. The second non-epileptic patient is 
a 6-year-old boy carrying a p.Thr1425Asn variant, also 
seen in a second patient who had epileptic spasms at 
5 months of age, but none since then.
Based on the existing reports as well as the case 
series reported here, pathogenic variants in CACNA1E 
appear to result in a disease with a spectrum of clinical 
manifestations ranging from severe refractory epilepsy 
Fig. 1 CACNA1E structure and reported variants (A) and their impact on the patients’ phenotypes (B). Underlined and in bold are the patients 
described in this study; other patients were described in Helbig et al. [12] and in Heyne et al. [11]. The phenotypes include global developmental 
delay (GDD), epilepsy, movement disorder (Mvt. disorder) including dyskinesia, developmental regression (Dev. Regr.), social deficit (Social Def.) 
including autism spectrum disorder, hyperactivity, and spastic quadriplegia (Spastic Q.). The lack of circle indicates that the related phenotype is not 
present in the patient(s) with the variant
Fig. 2 MTR‑plot of CACNA1E, reflecting intolerance of CACNA1E segments to missense variations. Horizontal dashed lines show CACNA1E MTR 
percentiles 5th (green line), 25th (yellow line) and 50th (black line), and the solid black line indicates mean MTR value of a given CACNA1E segment, 
intersegment and interdomain. Segments S6 in Domains I and II, intersegment S4‑S5 of Domain I as well as ends of Domains I and III, highlighted 
in dark red color, are considered highly intolerant to missense variation, as their MTR value is below 5th percentile with FDR < 0.1. Regions in darker 
brown color are considered as being under purifying selection as their mean MTR < 1 and FDR < 0.1 (S: segment, D: domain, ID: inter‑domain)
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with globally, severely disturbed development (DEE) to 
GDD with intellectual disability, developmental regres-
sion and ASD. This high phenotypic heterogeneity is 
not uncommon in both adult and developmental chan-
nelopathies [25], and it is made even more evident by 
the observation of different phenotypes resulting from 
identical mutations. Indeed, it is likely that other mech-
anisms including modifier genes, environmental factors 
or variations in gene expressivity contribute to the vari-
ability of the phenotypes. Considering the variability in 
the age of epileptic onset in the cohort of Helbig et al. 
[12], ranging from 1 day to 3 years, we cannot exclude 
that the younger patients in our cohort may develop 
seizures later in life.
The identification of a splicing variant adds further 
complexity to the pathogenic mechanisms. Our patient 
7 has a variant predicted to disrupt exon 22 consensus 
splicing donor site (c.3422+1G>A). Helbig et  al. have 
tested electrophysiologically the functional effects of the 
three CACNA1E missense variants in the segment 6 of 
Domain II and one variant located in the S4-S5 interseg-
ment of Domain II. These 4 missense variants all led to 
an increase in current density, facilitated channel activa-
tion and slower deactivation, and were thus consistent 
with gain-of-function effect of the variants. Additionally, 
the study also described three loss-of-function variants 
impacting CACNA1E and suggested that haploinsuf-
ficiency might be another pathogenic mechanism. The 
phenotypes of those three patients were milder than the 
others in their study and resemble that of the patients in 
our series. The presence of both haploinsufficiency vari-
ants as well as missense variants that may act through 
dominant negative or perhaps even gain-of-function 
mechanism is intriguing, but not novel. The existence of 
both loss-of-function and gain-of-function variants in 
calcium channel genes has been reported in CACNA1A 
for variants leading to variable severity of DEE [26], as 
well as in other neuronal channels (SCN8A [27], KCNQ2 
[28], KCNQ5 [29], KCNA2 [30], KCNB1 [31]). Interest-
ingly, gain-of-function changes in the electrophysiology 
of the cell can also result from loss-of-function effects of 
variants at the molecular level, and therefore, the gain-
of-function effect of truncating and/or splicing variants 
in CACNA1E should not be excluded without further 
functional studies of these variants. Based on the genetic 
epidemiology of variants in gnomAD and our computa-
tions, the CACNA1E gene seems to be constrained both 
against missense as well as against loss-of-function vari-
ants. Thus, the pathogenic mechanism remains unclear 
and this complicates genotype–phenotype correlation 
analysis. Such molecular understanding would be there-
fore needed in the future in order to design therapeutic 
approaches with drugs such as topiramate.
Furthermore, the observations in this small cohort 
challenge our current understanding of the interplay 
between epilepsy and its impact versus its co-occurrence 
with developmental delay. The term DEE was coined 
by the most recent classification from the International 
League Against Epilepsy (ILAE), defining relationship 
between developmental delay with or without early-life 
pharmacoresistant epilepsy [32]. However, recent publi-
cations of subjects harboring pathogenic variants in so-
called epilepsy genes who did not have seizures suggest 
that the concept of variants specific to epilepsy in the 
context of syndromic presentation may be mistaken. In 
that aspect, epilepsy, or ASD, might be considered as one 
of the phenotypic expressions of a monogenic syndrome 
[33]. The present work adds CACNA1E to the expanding 
list of genes implicated in an autosomal dominant neu-
rodevelopmental disorder, including ASD, with or with-
out epilepsy. Growing evidence suggests that diagnostic 
gene panels for epilepsy should be merged with larger 
brain development gene panels.
In Patient 1, treatment of topiramate [12] was intro-
duced with the hypothesis that modulation of the dys-
functional α1 subunit might improve the function of the 
neuronal connectivity underlying behavioral disorders, 
independently of the electroencephalographic activity 
as the patient never presented with any seizure. Parents 
reported a qualitative improvement concerning sleep 
quality and sphincter control; however, it might had hap-
pened by chance or as a natural evolution of the disorder. 
No additional effect has been observed on his behavioral 
disorder and development.
This study provides a further example of how match-
making tools like GeneMatcher can be used to define 
expanded phenotypes associated with described disease 
genes, like it has been previously described for LMNB1 
[34] and GATAD2B [35]. As NGS analysis is becoming 
routine worldwide and many laboratories are faced with 
variants that may not correspond to “typical” pheno-
types, these sharing and matchmaking tools will become 
even more important to facilitate the recognition of novel 
phenotypic associations and variant interpretation.
Limitations
The main limitation of our study is the absence of func-
tional studies of the effects and impacts of the identi-
fied variants on Cav2.3 channel function. Due to this 
lack of experimental data, we cannot assess whether 
the variants reported have a gain-of-function effect, as 
described in Helbig et al. [12]. Considering the similar 
types of variants (missense) and the consistent NDD 
phenotype, the de novo origin of these variants, their 
absence in control population, their impact on con-
served amino acid and deleterious predictions and the 
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presence of nearby pathogenic variants, our reported 
variants are classified as likely pathogenic/pathogenic 
according to ACMG criteria [18]. Functional experi-
ments are nevertheless essential to understand the 
pathomechanism behind the reported variants.
The second limitation of our study is the small cohort 
size. Gathering of patients through matchmaking plat-
forms comes with clear benefits but at the same time 
is limited by its multi-centric nature, which leads to 
involvement of variable specialists and assessment tools 
for each patient. Similarly, the individual submitting the 
information on the matchmaking platforms might not 
always be in direct contact with the patients and their 
referring clinicians, explaining the variability in clini-
cal assessments and detailed history of the patients, for 
example here the presence/absence of early regression 
or diagnostic criteria and full assessment for ASD. It 
thus shows how crucial the collaboration between clini-
cians and molecular specialists might be in the future.
Topiramate was tested in only one patient of the 
cohort, and no specific recommendations can be made, 
as the indication for its use was speculative. However, 
this information might support the use of this anti-sei-
zure medication drug in unusual indications.
In addition, our study highlights the role of both splic-
ing loss-of-function and missense variants but does not 
elucidate the underlying molecular mechanisms.
Conclusion
In this study, we identified heterozygous pathogenic 
or likely pathogenic de novo variants impacting CAC-
NA1E in seven patients presented with a phenotype 
that was less severe than that previously reported, nota-
bly with the absence of severe epilepsy, of macrocephaly 
and of spastic quadriplegia. The overlapping pheno-
types in our patients include GDD, abnormal social 
behavior including ASD, hypotonia and developmental 
regression. Furthermore, we analyzed the variant land-
scape of CACNA1E and showed strong constraint of 
missense variants in specific segments of CACNA1E. 
We conclude that CACNA1E variants have a broader 
phenotypic spectrum than previously reported, includ-
ing non-epileptic ASD and GDD, and this may inform 
the composition of diagnostic gene panels and the 
interpretation of variants observed in NGS studies.
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